Table I.

Crry-Ig Specifically Prevents aPL Antibody-induced Fetal Resorption and Growth Retardation

Human IgG source:	aPL	aPL	Cntrl IgG	Cntrl IgG
Mouse reagent:	mIgG	Crry-Ig	mIgG	Crry-Ig
Number of mice	11	14	10	11
Frequency of fetal resorption	0.29 ± 0.09a	0.08 ± 0.03	0.10 ± 0.05	0.08 ± 0.03
Fetal weight (mg)	171 ± 27a	256 ± 38	273 ± 32	281 ± 34

Female BALB/c mice were given aPL-IgG (10 mg) or normal human IgG (Cntrl IgG) (10 mg) intraperitoneally on days 8 and 12 of pregnancy. Mice also received either Crry-Ig (3 mg) or polyclonal murine IgG (mIgG) (3 mg) intraperitoneally every other day from days 8–12. Mice were killed on day 15 of pregnancy, uteri were dissected, fetuses were weighed, and frequency of fetal resorption calculated (number of resorptions/number of fetuses plus number of resorptions). Treatment with aPL-IgG caused an increase in fetal resorptions and a decrease in fetal weight (^aaPL plus mIgG versus Cntrl IgG plus mIgG; P < 0.001) which was prevented by Crry-Ig (^aaPL plus mIgG versus aPL plus Crry-Ig; P < 0.001). Treatment with mIgG did not affect either pregnancy outcome.